About the Company
Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer. The Company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance. Constellation is driving development of the BET inhibitor CPI-0610 for the treatment of myelofibrosis as well as the EZH2 inhibitor CPI-0209 for the treatment of solid tumors. The Company is also applying its broad research and development capabilities to explore other novel targets that directly and indirectly impact gene expression to fuel a sustainable pipeline of innovative small-molecule product candidates.
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
Employees
106
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $CNST News
Constellation Pharmaceuticals gets grant for novel compounds for treating diseases associated with methyl modifying enzymes
Discover how Constellation Pharmaceuticals Inc's patented compounds are revolutionizing cancer treatment. Learn about the versatile applications and potential for treating various types of cancer.
Constellation Brands' Fiscal 2024 Earnings: Growth in Beer Segment Drives Profitability
Constellation Brands' net sales rose by 5.4% to $9.96 billion. Additionally, operating income, which measures the profit a company makes from its core business functions, increased by 11.5% to $3.17 ...
Constellation Brands moves itself further away from cannabis grower Canopy Growth’s business
Alcoholic-beverage giant Constellation Brands Inc. on Thursday announced a number of moves intended to further wash its hands ...
Constellation Brands Inc Class A STZ
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Constellation Software Inc. Announces Release Date for First Quarter Results
TORONTO, April 16, 2024 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX:CSU) announced today it intends to release its first quarter results on May 10, 2024.
Stocks to Watch Thursday: Robinhood, Alpine Immune, Constellation Brands
Constellation Brands (STZ): The Modelo maker posted better-than-expected quarterly sales, as strength in its beer brands helped offset challenges in wine and spirits. Its stock rose 2%.
Constellation Software Inc., Topicus.Com Inc. And Lumine Group Inc. Announce Annual Meetings
The Constellation Software Inc. (“Constellation” or“CSI”) (TSX:CSU) annual meeting of shareholders will be held on Monday, May 13, 2024 at 9:00 a.m. EST using a virtual meeting format ...
Plc Gsk's Net Worth
Plc Gsk has an estimated net worth of $9.11 Billion. This is based on reported shares across multiple companies, which include Wave Life Sciences Ltd., CVRx, Inc., Lyell Immunopharma, Inc ...
Constellation Brands, Inc. (STZ)
VICTOR, N.Y., April 18, 2024 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE: STZ), a leading beverage alcohol company, announced today that its indirect, wholly ...
Constellation Brands Inc - Class A
Constellation Brands Inc is a leading beverage company, known for its wide range of beer, wine, and spirits. With popular beer brands like Corona and Modelo, and wine and spirits labels such as ...
Loading the latest forecasts...